AtriCure, Inc.
ATRCHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AtriCure, Inc. focuses on Medical Instruments & Supplies services and products. AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral. The company carries a $2.62B market cap, placing it firmly in the mid-cap category. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
Market Cap
$2.62B
Beta
1.26
P/E (TTM)
245.33
P/E (Fwd)
119.33
EPS (TTM)
$0.21
EPS (Fwd)
$0.43
ROE
2.1%
ROA
1.3%
Cash
$167.8M
Total Debt
$74.2M
Free CF
$48.8M
52W Change
42.7%
Annual Financials
Cash vs Debt
Where ATRC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ATRC finished 60.04% above its 150-day moving average ($32.86) and 53.19% above its 200-day moving average ($34.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATRC overbought or oversold?
At the September 3, 2026 close, ATRC's RSI(14) was 84.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $167.8M in cash and $74.2M in debt, ATRC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $48.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $330.4M (2022) to $534.5M (2025), reflecting a 62% increase over the period.
With cash comfortably exceeding debt, ATRC has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ATRC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.